InsiderPulse
Dashboard

DNTH

Dianthus Therapeutics, Inc.

Health CareRussell 2000

Dianthus Therapeutics, Inc. insider trading

Dianthus Therapeutics, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in New York, NY. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent DNTH insider transactions

6 insiders traded DNTH on the open market between Aug 07, 2026 and Sep 17, 2026 — 24 sales worth $9.3M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$9.3M

24 of 24 on a 10b5-1 plan

Net
−$9.3M
Insiders
6

Open-market purchases (code P) and sales (code S) from Dianthus Therapeutics, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every DNTH Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

DNTH insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 6 insiders traded DNTH on the open market: 0 purchases and 34 sales worth $42.6M, every sale pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 34 sales ($42.6M), by 6 insiders.

QuarterBoughtSold
Q2 2026—−$5.6M7 sales · all on a plan
Q1 2026—−$28M21 sales · all on a plan
Q4 2025—−$8.3M5 sales · all on a plan
Q3 2025—−$700K1 sale · all on a plan
Q2 2025——
Q1 2025——
Q4 2024——
Q3 2024——
Largest sale
−$5.4M of DNTH by Garcia Marino (CEO And President · Director) on Mar 12, 2026, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Veness Adam M10b5-1

    SVP, General Counsel and Sec.

    −$1.3M

    Jun 17, 2026

    16,771 sh · $80.34

  • Veness Adam M10b5-1

    SVP, General Counsel and Sec.

    −$1.1M

    Jun 17, 2026

    13,229 sh · $81.38

  • Randhawa Simrat10b5-1

    EVP, Head of R&D

    −$1.5M

    Jun 01, 2026

    16,943 sh · $90.72

  • Randhawa Simrat10b5-1

    EVP, Head of R&D

    −$487K

    Jun 01, 2026

    5,428 sh · $89.72

  • Randhawa Simrat10b5-1

    EVP, Head of R&D

    −$380K

    Jun 01, 2026

    4,159 sh · $91.37

  • Soteropoulos Paula10b5-1

    Director

    −$51.2K

    May 08, 2026

    599 sh · $85.47

  • Savitz Ryan10b5-1

    EVP, CFO & Cbo

    −$738.8K

    Apr 09, 2026

    8,224 sh · $89.84

  • Savitz Ryan10b5-1

    EVP, CFO & Cbo

    −$5M

    Mar 31, 2026

    59,800 sh · $83.90

  • Savitz Ryan10b5-1

    EVP, CFO & Cbo

    −$1.7M

    Mar 31, 2026

    21,825 sh · $78.86

  • Savitz Ryan10b5-1

    EVP, CFO & Cbo

    −$1.6M

    Mar 31, 2026

    19,469 sh · $84.57

  • Savitz Ryan10b5-1

    EVP, CFO & Cbo

    −$618.6K

    Mar 31, 2026

    7,232 sh · $85.54

  • Savitz Ryan10b5-1

    EVP, CFO & Cbo

    −$196K

    Mar 31, 2026

    2,366 sh · $82.84

  • Savitz Ryan10b5-1

    EVP, CFO & Cbo

    −$119.2K

    Mar 31, 2026

    1,485 sh · $80.25

  • Savitz Ryan10b5-1

    EVP, CFO & Cbo

    −$108.9K

    Mar 31, 2026

    1,390 sh · $78.33

  • Savitz Ryan10b5-1

    EVP, CFO & Cbo

    −$65.1K

    Mar 31, 2026

    800 sh · $81.36

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Dianthus Therapeutics, Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
New York, NY
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001690585
Previously filed as
Magenta Therapeutics, Inc.

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought DNTH

What the stock actually did in the 90 days following each open-market purchase

Don't check DNTH — let it ping you

Get told the moment an insider moves on DNTH

Pro watches Dianthus Therapeutics, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add DNTH to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track DNTH on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read DNTH insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

UTHRCORTHRMYSUPNOMCLHQYDOCSOSCRALHCASTHBDXTECH
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are DNTH insiders buying or selling?
Between Aug 07, 2026 and Sep 17, 2026, 6 Dianthus Therapeutics, Inc. insiders made no open-market purchases and 24 sales worth $9.3M, a net sale of $9.3M. 24 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much DNTH stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 6 Dianthus Therapeutics, Inc. insiders made no open-market purchases and 34 sales worth $42.6M. Every one of the sales was pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 34 sales ($42.6M). The largest sale was Garcia Marino selling $5.4M on Mar 12, 2026.
What was the largest recent DNTH insider trade?
Veness Adam M (SVP, General Counsel and Sec.) sold $1.8M of DNTH stock on Aug 10, 2026 at about $110.38 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy DNTH shares?
No open-market purchase by a Dianthus Therapeutics, Inc. insider appears in the filings from Aug 07, 2026 to Sep 17, 2026 — every recorded open-market transaction in that period was a sale.
Where does DNTH insider trading data come from?
From the Form 4 filings Dianthus Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.